Surgery in recurrent epithelial ovarian cancer: Benefits on Survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction - Concepedia

Concepedia

Publication | Closed Access

Surgery in recurrent epithelial ovarian cancer: Benefits on Survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction

49

Citations

22

References

2010

Year

Wen‐Juan Tian, Rong Jiang, Xi Cheng, Jie Tang, Yan Xing, Rongyu Zang

Journal of Surgical Oncology

Abstract

Complete secondary cytoreduction is the strongest survival determinant in recurrent epithelial ovarian cancer, whereas patients with residual disease of 0.1-1 cm may also benefit from secondary cytoreduction.

References

	Year	Citations
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study William E. Winter, G. Larry Maxwell, Chunqiao Tian, Journal of Clinical Oncology	2007	839
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Mark F. Brady, Harrison Ball, Jonathan S. Berek American Journal of Obstetrics and Gynecology Surgical OncologyPrimary Cytoreductive SurgeryTumoral PathologyGynecological SurgeryMedicine	1994	670
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? D.S. Chi, Eric Eisenhauer, J. Lang, Gynecologic Oncology Gynecologic SurgerySurgical OncologyPrimary Cytoreductive SurgeryGynecological SurgeryMedicine	2006	624
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma International Journal of Gynecology & Obstetrics Surgical OncologyPrimary Cytoreductive SurgeryTumoral PathologyGynecological SurgeryMedicine	1995	555
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial Philipp Harter, Andreas du Bois, Maik Hahmann, Annals of Surgical Oncology Gynecologic SurgerySurgical OncologyGynecological SurgeryMedicineDesktop Ovar Trial	2006	415
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma S. Dennis, Kristina McCaughty, John P. Diaz, Cancer	2006	355
Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures Olivier Gléhen, D. Osinsky, Eddy Cotte, Annals of Surgical Oncology Surgical OncologyIntraperitoneal ChemohyperthermiaGastrointestinal OncologyConsecutive ProceduresMedicine	2003	341
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. G A Omura, B. Bundy, Jonathan S. Berek, Journal of Clinical Oncology Randomized Clinical TrialSurgical OncologyCancer ManagementGynecologyPathology	1989	327
The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma Scott M. Eisenkop, Richard L. Friedman, Nick M. Spirtos Cancer	2000	280
Survival of patients following secondary cytoreductive surgery in ovarian cancer. JS Berek, Neville F. Hacker, Lagasse Ld, PubMed Gynecologic SurgerySurgical OncologyGynecological SurgeryMedicineGynecology	1983	274

Page 1